EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Blood pressure monitoring in elderly migraineurs starting an anti-CGRP monoclonal antibody: a real-world prospective study

Davide Mascarella, Giorgia Andrini, Carlo Baraldi, Claudia Altamura, Valentina Favoni, Flavia Lo Castro, Giulia Pierangeli, Fabrizio Vernieri, Simona Guerzoni, Sabina Cevoli

Neurological Sciences · 2024-11 · 45 (11) · 5365-5373

DOI: 10.1007/s10072-024-07567-9 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Neurological Sciences, online erschienen am 25.05.2024. Verfasst von Davide Mascarella und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Neuromotor Science DIBINEM, Alma Mater Studiorum Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Migraine Disorders, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Blood Pressure. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alma Mater Studiorum - Università di Bologna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While monoclonal antibodies (mAbs) targeting the CGRP pathway have revolutionized migraine management due to their improved tolerance and adherence, concerns remain about their potential impact on blood pressure (BP), especially in older patients, due to CGRP-mediated vasodilation blockade. Given the growing use of these therapies in older populations, assessing their cardiovascular (CV) safety is of paramount importance.

Methods

This multicentric observational prospective study focused on migraine sufferers aged ≥ 60 who began erenumab, galcanezumab, or fremanezumab for prevention. Baseline, three-month, and twelve-month BP measurements were collected. Changes in antihypertensive medication and "Newly or Worsened Hypertensive" patients (NWHP) were assessed.

Results

Among 155 patients receiving anti-CGRP mAbs (40 Erenumab, 47 Galcanezumab, 68 Fremanezumab), 42.5% had hypertension history and 39% were on antihypertensive treatment. No significant systolic or diastolic BP changes occurred at any time point compared to baseline (all p > 0.05), with no differences between the three groups. After one year, 20/155 (12.9%) patients were considered NWHP; 11/20 had prior hypertension, and 5/11 adjusted antihypertensive therapy. Among 9/20 newly hypertensive patients, 5/9 had a single measurement above the normal threshold with no requirement for new pharmacological therapy. A higher baseline BP value was associated with increased BP ( p = 0.002).

Conclusions

The study concludes that treatment with anti-CGRP mAbs over one year does not significantly affect BP in patients aged ≥ 60, nor does it increase the incidence of hypertension compared to general population trends. Nonetheless, continuous monitoring and further long-term studies are necessary to fullya scertain the cardiovascular safety of these medications in the elderly.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBlood PressureHumansMaleFemaleAgedProspective StudiesMiddle AgedHypertensionCalcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor AntagonistsAntihypertensive Agents

Stichwörter der Autor:innen

Anti-CGRPBlood pressureCGRPCardiovascular safetyElderlyErenumabFremanezumabGalcanezumabHypertensionMigraine

Substanzen

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedgalcanezumaberenumabfremanezumabCalcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor AntagonistsAntihypertensive Agents

Autor:innen und Institutionen

  • Department of Biomedical and Neuromotor Science DIBINEM, Alma Mater Studiorum Bologna, Bologna, Italy.
  • Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, Department of Specialist Medicines, AOU Policlinic…
  • Unit of Headache and Neurosonology, Department of Medicine and Surgery, Università Campus Bio-Medico Di Roma, Via Alvaro del Portillo, 21, 00128, Rome, Italy.
  • Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200, 00128, Rome, Italy.
  • IRCCS Istituto Delle Scienze Neurologiche Di Bologna ISNB, Bologna, Italy.
  • IRCCS Istituto Delle Scienze Neurologiche Di Bologna ISNB, Bologna, Italy. sabina.cevoli@unibo.it.

Förderung

  • Alma Mater Studiorum - Università di Bologna

Zitieren

APA

Mascarella, D., Andrini, G., Baraldi, C., Altamura, C., Favoni, V., Lo Castro, F., Pierangeli, G., Vernieri, F., Guerzoni, S., & Cevoli, S. (2024). Blood pressure monitoring in elderly migraineurs starting an anti-CGRP monoclonal antibody: a real-world prospective study. Neurological Sciences, 45(11), 5365-5373. https://doi.org/10.1007/s10072-024-07567-9

Vancouver

Mascarella D, Andrini G, Baraldi C, Altamura C, Favoni V, Lo Castro F, et al. Blood pressure monitoring in elderly migraineurs starting an anti-CGRP monoclonal antibody: a real-world prospective study. Neurological Sciences. 2024;45(11):5365-5373. doi:10.1007/s10072-024-07567-9

BibTeX
@article{Mascarella2024,
  author = {Mascarella, Davide and Andrini, Giorgia and Baraldi, Carlo and Altamura, Claudia and Favoni, Valentina and Lo Castro, Flavia and Pierangeli, Giulia and Vernieri, Fabrizio and Guerzoni, Simona and Cevoli, Sabina},
  title = {Blood pressure monitoring in elderly migraineurs starting an anti-CGRP monoclonal antibody: a real-world prospective study},
  journal = {Neurological Sciences},
  year = {2024},
  volume = {45},
  number = {11},
  pages = {5365--5373},
  doi = {10.1007/s10072-024-07567-9}
}
Kostenlos starten →